Pharmaceutical business drives recovery: Bayer raises annual forecast after strong quarter
Reading Time: 3 minutes
Forecast increase for 2026: Thanks to flourishing pharmaceutical businesses, Bayer raises its adjusted EBITDA target to 9.8 to 10.3 billion euros. New drugs cushion Xarelto: The revenue drivers Nubeqa and Kerendia boost the operational segment results; Nubeqa alone generated around one billion euros. Analysts praise the pipeline: BofA Global Research considers the potential of the pharmaceutical division to be massively underestimated, pointing to multi-year cash flow fantasies. A surprisingly dynamic development...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
